S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Laser breakthrough could send stock soaring 2,467% (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Laser breakthrough could send stock soaring 2,467% (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Laser breakthrough could send stock soaring 2,467% (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Laser breakthrough could send stock soaring 2,467% (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News

$4.87
-0.17 (-3.37%)
(As of 09/22/2023 ET)
Compare
Today's Range
$4.81
$5.17
50-Day Range
$4.65
$8.15
52-Week Range
$4.41
$10.41
Volume
8.71 million shs
Average Volume
7.91 million shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.54

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
301.2% Upside
$19.54 Price Target
Short Interest
Bearish
14.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.33mentions of Iovance Biotherapeutics in the last 14 days
Based on 24 Articles This Week
Insider Trading
Acquiring Shares
$26.56 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

85th out of 967 stocks

Biological Products, Except Diagnostic Industry

8th out of 155 stocks


IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Price History

IOVA Stock News Headlines

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Update
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Iovance Biotherapeutics' (IOVA) "Buy" Rating Reiterated at Mizuho
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
8/08/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
503
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$19.54
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+301.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$-395,890,000.00
Pretax Margin
-176,181.52%

Debt

Sales & Book Value

Annual Sales
$238,000.00
Book Value
$2.66 per share

Miscellaneous

Free Float
222,008,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
0.10

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 49)
    J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 50)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 50)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 56)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    VP of Investor Relations & PR
  • Ms. Tracy Winton
    Sr. VP of HR
  • Mr. Howard B. Johnson M.B.A. (Age 63)
    Chief Bus. Officer
  • Mr. James Ziegler M.B.A.
    Exec. VP of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Sr. VP & Head of Digital and Information Technology













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

13 Wall Street analysts have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they predict the company's stock price to reach $19.54 in the next twelve months. This suggests a possible upside of 301.2% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2023?

Iovance Biotherapeutics' stock was trading at $6.39 at the beginning of the year. Since then, IOVA stock has decreased by 23.8% and is now trading at $4.87.
View the best growth stocks for 2023 here
.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 30,070,000 shares, an increase of 9.2% from the August 15th total of 27,530,000 shares. Based on an average daily trading volume, of 4,880,000 shares, the days-to-cover ratio is presently 6.2 days. Approximately 14.7% of the shares of the company are sold short.
View Iovance Biotherapeutics' Short Interest
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.34. The biotechnology company earned $0.24 million during the quarter, compared to analysts' expectations of $3.91 million. During the same period in the prior year, the firm posted ($0.63) EPS.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.86%), Perceptive Advisors LLC (5.66%), State Street Corp (5.47%), Point72 Asset Management L.P. (3.14%), Artisan Partners Limited Partnership (1.79%) and Geode Capital Management LLC (1.67%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $4.87.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.21 billion and generates $238,000.00 in revenue each year. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 503 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -